Abstract: Embodiments of the present invention include the use of placental alkaline phosphatase alone or in combination with human transferrin and, optionally, human ?1-antitrypsin to enhance the proliferation and survival of transplanted stem cells and stem cell-derived progenitor cells.

Abstract: Methods of delaying the onset or treating the progression of Type 2 diabetes in subjects that have increased blood levels of an inflammation marker protein. In one embodiment, the method includes administering an inhibitor OF ?1-antitrypsin (AT) to the subject, and optionally co-administering an anti-diabetic medicament or anti-inflammatory agent to the subject. Treatment regimens provided by the invention may be used to delay the onset of or to control Type 2 diabetes. The invention provides for the use of an inhibitor of ?1-antitrypsin, such as gemfibrozil (GF), for the manufacture of a medicament for the uses described herein. The invention further provides combinations of agents for treating or delaying the progression or onset of diabetes, comprising an inhibitor of ?1-antitrypsin and an anti-inflammatory agent and/or an anti-diabetic medicament.

Abstract: Embodiments of the present invention include the use of heterocyclic trialkyl ammonium-containing compounds to promote regeneration of bone marrow from endogenous or exogenous stem/progenitor cells and to normalize blood cell and platelet counts.

Abstract: Embodiments of the present invention include the use of heterocyclic trialkyl ammonium-containing compounds to promote regeneration of bone marrow from endogenous or exogenous stem/progenitor cells and to normalize blood cell and platelet counts.

Abstract: Embodiments of the invention provide a method and composition for treating or reducing multiple drug resistance in cancers. Embodiments of the invention also provide for a xanthene compound to inhibit multidrug resistance protein 1.

Abstract: Method for modulating the migration of neural progenitor cells in a mammal by exposing the cells to a VEGFR-2 ligand and FGF-2. Methods of treating neurological disorders by exposing the mammal to a VEGFR-2 ligand in the presence of FGF-2 are also provided. A composition including a biocompatible matrix associated with FGF-2 is also provided.

Abstract: Methods for stimulating proliferation of cells in the epidermis and dermis of mammalian skin are disclosed. The methods comprise the step of administering to an area of the skin a composition comprising a therapeutically effective amount of human placental alkaline phosphatase, or an active derivative. The composition can be administered topically or by injection. The invention also provides a regimen for restoring or maintaining the strength and thickness of aging skin, comprising periodically administering a composition by topical application. The invention further provides methods for stimulating proliferation of cells in the epidermis and dermis of transplanted skin. A composition for topical application is also provided by the invention.

Abstract: One embodiment of the invention uses thioxanthone compounds containing a choline or choline analogue moiety, such as CCcompound1 or [3-(3,4-Dimethyl-9-oxo-9H-thioxanthen-2-yloxy)-2-hydroxypropyl]trimethyl-ammonium chloride, to reduce or reverse body weight loss in various mouse models of human tumors. Another embodiment of the invention discloses a method for reducing or reversing cachexia or disease-induced body weight loss in human and other mammals using thioxanthone compounds containing a choline analogue moiety.

Abstract: Embodiments of the invention provide mouse tumor models involving either the B16 mouse melanoma or MXT mouse mammary tumor, untreated or treated with chemotherapy and/or anti-cachectic agents, for the study of tumor-generated or cancer therapy-generated cachexia-inducing signals and mechanisms. Other embodiments of the invention also provide additional models, including pre-treatment of mouse skin with anti-cachectic proteins prior to tumor implantation, for the study of anti-cachectic signals and mechanisms generated by the skin. To reduce or reverse tumor- and chemotherapy-induced cachexia, embodiments of the invention use the human proteins placental alkaline phosphatase, transferrin, ?1-antitrypsin preparations or combinations thereof as well as chemically synthesized CCDTHT or N,N-diethyl-N-methyl-2-[(9-oxo-9H-thioxanthen-2-yl)methoxy]-ethanaminium iodide or CCDTHT-like compounds.

Abstract: Methods for promoting survival and stimulating proliferation of cells in the epidermis and dermis of undamaged mammalian skin are disclosed. The methods comprise the step of administering to an area of the skin a composition comprising a therapeutically effective amount of human placental alkaline phosphatase, or an active derivative. The composition can be administered topically or by injection. Embodiments of the invention also provide regimens for restoring or maintaining the strength and thickness of aging skin, comprising periodically administering a composition by topical application. Other embodiments of the invention further provide methods for promoting survival and stimulating proliferation of cells in the epidermis and dermis of transplanted skin. A composition for topical application is also provided by some embodiments of the invention.

Abstract: Methods of using alpha-1-acid glycoprotein, or an active derivative, to modulate the blood glucose level in mammals, particularly humans, is described. A therapeutically effective amount of alpha-1-acid glycoprotein is administered to a patient afflicted with Type 1 or Type 2 diabetes to lower the blood glucose level. An anti-diabetic medicament, particularly insulin, may also be administered in combination with alpha-1-acid glycoprotein. The invention also provides a treatment regimen by periodically administering alpha-1-acid glycoprotein and further provides a method of mitigating the inhibitory effect of an acute phase protein on the action of insulin.

Abstract: Methods for stimulating proliferation and inhibiting death of cells in the epidermis and dermis of wounded and non-wounded as well as transplanted mammalian skin and transplanted skin cell suspensions are described. The methods include the steps of administering to an area of wounded or non-wounded skin therapeutically effective amounts of ?1-antitrypsin, alkaline phosphatase (such as placental alkaline phosphatase), transferrin, and ?1-acid glycoprotein in compositions that contain at least two of these proteins, or their active derivatives, as the major active components. The compositions can be administered topically and/or by injection, or both. The invention also provides regimens for restoring or maintaining the strength and thickness of wounded, non-wounded and transplanted skin as well as developing new skin from skin cell suspensions comprising periodically administering one or more compositions topically and/or by injection.

Abstract: Embodiments of the present invention include the use of a composition of placental alkaline phosphatase or other members of the alkaline phosphatase family alone, or in combination with human transferrin and, optionally, human ?1-antitrypsin to enhance the in vitro proliferation and survival of adult or embryonic stem cells and/or progenitor cells that are derived from stem cells.

Abstract: Embodiments of the present invention use transferrin or active derivatives to control or stabilize abnormally elevated levels of blood glucose in mammals, particularly humans. Embodiments of the invention also provide methods for enhancing survival of islet ?-cells in vivo and in vitro. In other embodiments, transferrin or active derivatives are used in combination with anti-diabetic medicaments or performing an insulin elevating procedure. In yet another embodiment the invention includes administering transferrin or an active derivative to reduce weight loss induced by type 1 diabetic condition.

Abstract: This invention uses placental alkaline phosphatase (“PALP”), and other members of the alkaline phosphatase family, to reduce the death and thereby maintain or enhance the viability and function of insulin-producing islet ?-cells including insulin secretion. PALP may be administered to a patient that has received transplanted islet cells to protect the transplanted islets against ROS-mediated attacks by the patient's immune system. Transferrin and other promoters of islet survival may also be used to enhance the effects of PALP on islet viability both in vivo and in vitro.

Abstract: Embodiments of the present invention relate to the use of placental alkaline phosphatase, and other members of the alkaline phosphatase family, to enhance protein synthesis in the muscle as well as the survival of non-cancerous differentiated cells in the muscle, adipose and other tissues. The ability of alkaline phosphatase to selectively enhance the survival of healthy cells and increase protein synthesis has many therapeutic applications. The use of alkaline phosphatase may prevent the loss of body weight and muscle mass typically experienced by diseased (such as cancer) or aging patients, or developing fetuses subjected to harmful conditions, or by patients who are treated with a toxic therapy including chemotherapy.

Abstract: A method for reducing shunt-related defects is described for hydrogenated amorphous silicon (a-Si:H) thin film photovoltaic modules with thin active a-Si:H absorber as required by building integrated photovoltaic windows and sun-roofs with adequate transmission of sunlight. Without shunt-passivation, p-i-n type large area photovoltaic modules with very thin a-Si:H i-layer will suffer excessive performance, yield, and reliability losses due to electrical shorting through i-layer defects. Wide-bandgap a-Si:H based alloy films of sufficient resistivity are deposed between the active solar cell and the conductive back electrode to provide a barrier to leakage current flow. Such a-Si:H based barrier films of high optical transparency are dummy films that do not directly contribute to energy conversion. The shunt-passivation films are entirely produced by the same conventional manufacturing process for a-Si:H photovoltaic devices without invoking complicated or exotic materials or procedures proposed in prior arts.

Abstract: A class of compounds commonly containing a trialkylammonium group have been synthesized and characterized as anticancer compounds. A representative of this class, N,N-diethyl-N-methyl-2-[(9-oxo-9H-thioxanthen-2-yl)methoxy]ethanaminium iodide (CCDTHT) was shown in various tumor models to decrease tumor volume, enhance the effects of other chemotherapeutic agents including cisplatin, reduce chemotherapy-induced loss of body weight, and increase survival of animals co-treated with toxic amounts of cisplatin. CCDTHT had even greater effects on tumor volume, body weight, and survival when administered to animals together with the human protein placental alkaline phosphatase. These trialkylammonium group-containing compounds and alkaline phosphatases, particularly in combination with each other and other therapies, may be used to treat cancer and other cell proliferative diseases.

Abstract: Methods and regimens for stimulating proliferation and inhibiting death of skin cells in wounded, non-wounded healthy and unhealthy, or transplanted skin and skin cell suspensions are provided. The methods and regimens include a step of administering to an area of host skin and/or transplanted skin a combination of lactoferrin and alkaline phosphatase such as placental alkaline phosphatase. The active components may be administered topically, by injection, or by other suitable means. In addition to improving the quality of skin, the reported methods may also be effective to reduce inflammation and microbial infection in the skin. Embodiments of the invention also provide compositions suitable for use in the described methods.

Abstract: Methods for stimulating proliferation and inhibiting death of cells in the epidermis and dermis of wounded and non-wounded as well as transplanted mammalian skin and transplanted skin cell suspensions are described. The methods include the steps of administering to an area of wounded or non-wounded skin therapeutically effective amounts of ?1-antitrypsin, alkaline phosphatase (such as placental alkaline phosphatase), transferrin, and ?1-acid glycoprotein in compositions that contain at least two of these proteins, or their active derivatives, as the major active components. The compositions can be administered topically and/or by injection, or both. The invention also provides regimens for restoring or maintaining the strength and thickness of wounded, non-wounded and transplanted skin as well as developing new skin from skin cell suspensions comprising periodically administering one or more compositions topically and/or by injection.